U.S. Capital Markets Stock News

Enovix (ENVX) opened Q1 2026 with revenue of US$7.6 million and a basic EPS loss of US$0.18, alongside a net loss of US$38.26 million. On a trailing 12 month basis, the company generated US$34.32 million of revenue and a basic EPS loss of US$0.81 tied to a US$171.49 million net loss. Over recent quarters, the company has seen revenue range from US$5.10 million to US$11.27 million with quarterly basic EPS losses between US$0.12 and US$0.26. This provides a clear view of how growth and losses...

Akamai Technologies (NasdaqGS:AKAM) has agreed to acquire LayerX, a provider of browser-based AI usage control and secure enterprise browser technology. The deal extends Akamai’s Zero Trust portfolio into browser-level protection for generative AI applications used inside enterprises. The acquisition targets growing enterprise concerns around how employees access and use AI tools through their web browsers. Akamai Technologies, trading at $155.67, has seen strong recent share price...

Similarweb Q1 2026: Revenue Edges Higher While Losses Persist Similarweb (SMWB) opened 2026 with Q1 revenue of US$73.9 million and a basic EPS loss of US$0.07, while trailing 12 month revenue sat at US$289.4 million and EPS at a loss of US$0.35. The company has seen quarterly revenue move from US$67.1 million in Q1 2025 to US$73.9 million in Q1 2026, with basic EPS losses over that span ranging between US$0.05 and US$0.14 per quarter as management works toward narrowing the gap between top...

Spectral Capital (OTCPK:FCCN) has just posted Q1 2026 revenue of roughly US$328.5 million, alongside a basic EPS loss of US$0.11 and a net loss of about US$9.4 million, setting a clear tone for the quarter. The company has seen revenue move from US$0 in Q1 2025 to US$328.5 million in Q1 2026, while basic EPS has shifted from a loss of US$0.01 to a deeper loss of US$0.11, indicating that margins are under pressure even as the top line scales rapidly. See our full analysis for Spectral...

Bullish (BLSH) opened 2026 with Q1 revenue of US$77.5 million, a basic EPS loss of US$3.85, and a net loss of US$581.7 million, setting a tough but clear baseline for investors watching how the story develops from here. Over the past year, the company has seen quarterly revenue move from US$39.3 million in Q4 2024 to US$77.5 million in Q1 2026, while EPS has swung between a profit of US$1.39 and losses such as US$3.85, highlighting how quickly margins can shift as the business scales. With...

If you are wondering whether Natural Resource Partners at around US$107.20 is still offering fair value or starting to look stretched, you will want to focus on what the numbers actually say about its valuation. The stock is up 3.1% year to date and around 15.3% over the past year, even though it has fallen about 5.4% over the last week and 7.4% over the past month, which may have shifted how the market is pricing in its risks and opportunities. Recent news around Natural Resource Partners...

Black Rock Coffee Bar (BRCB) opened Q1 2026 with revenue of US$55.5 million and basic EPS of US$0.02, alongside net income of US$0.4 million. These results put fresh numbers behind a company that has recently moved into profitability on a trailing twelve month basis. The company has seen quarterly revenue move from US$42.8 million in Q4 2024 to US$51.5 million in Q3 2025 and then US$53.6 million in Q4 2025. Trailing twelve month EPS shifted from a loss of US$0.33 in Q2 2025 to a small profit...

Kadant (KAI) opened Q1 2026 with revenue of US$281.5 million and basic EPS of US$2.16, while trailing twelve month EPS sat at US$8.78 on revenue of US$1.1 billion and net income of US$103.4 million. Over the last five reported quarters, revenue has ranged from US$239.2 million to US$286.2 million as basic EPS moved between US$2.04 and US$2.35. This gives investors a clear read on how the top and bottom lines have tracked together into this latest print. With trailing net margins at 9.4%...

In the first quarter of 2026, monday.com reported revenue of US$351.27 million and net income of US$28.03 million, while also lifting its full‑year revenue outlook. Ahead of this earnings release, the company unveiled its largest product overhaul yet, rebranding as an AI Work Platform with native, configurable AI agents and a new consumption-based pricing model aimed at monetizing AI usage across its customer base. We’ll now examine how monday.com’s launch of its AI Work Platform and...

REGENXBIO (RGNX) Q1 2026 earnings snapshot REGENXBIO (RGNX) has just posted Q1 2026 results with revenue of US$6.4 million and a basic EPS loss of US$1.72, against a trailing twelve month basic EPS loss of US$5.59 on revenue of US$87.8 million. Over recent quarters the company has reported revenue of US$89.0 million in Q1 2025, followed by US$21.4 million in Q4 2024. Basic EPS moved from a profit of US$0.12 in Q1 2025 to a loss of US$1.01 in Q4 2024. These figures are likely to draw investor...

Axon Enterprise reported past first-quarter 2026 results showing revenue of US$807.35 million versus US$603.63 million a year earlier, with net income rising from US$87.98 million to US$169.31 million and diluted earnings per share from continuing operations increasing from US$1.08 to US$2.05. The company also lifted its full-year 2026 revenue growth outlook to a range of 30% to 32%, underscoring how its expanding AI-driven product suite is reshaping Axon’s business mix and earnings...

Leggett & Platt, Incorporated has reported past first-quarter 2026 results showing sales of US$918.2 million, down from US$1,022.1 million a year earlier, with net income falling from US$30.6 million to US$20 million. The simultaneous decline in both revenue and profitability gives investors a fresh data point on how the company is managing current demand conditions and cost pressures. We’ll now examine how this quarter’s weaker sales and earnings reshape Leggett & Platt’s investment...

Recent share performance and business profile Novo Nordisk (NYSE:NVO) has drawn investor attention after a mixed stretch for the stock, with the share price down 12.6% year to date yet up 16.5% over the past month. The Denmark based pharmaceutical group reports US$327.8b in revenue and US$121.96b in net income, primarily from its Diabetes and Obesity Care segment, alongside a smaller Rare Disease business. See our latest analysis for Novo Nordisk. At a share price of US$45.80, Novo Nordisk...

Nebius Group (NasdaqGS:NBIS) has opened 2026 with Q1 revenue of US$399 million and Basic EPS of US$2.40, alongside net income of US$621.2 million, setting a clear marker after a volatile run of prior quarters. The company has seen revenue move from US$55.3 million in Q1 2025 and US$35.2 million in Q4 2024 to US$399 million in Q1 2026, with Basic EPS shifting from a loss of US$0.48 in Q1 2025 and a loss of US$0.58 in Q4 2024 to a profit of US$2.40. This puts the focus firmly on how sustainable...

Cooper Companies (NasdaqGS:COO) has appointed Paul Keel to its Board of Directors. Keel will also serve on the Board’s Audit Committee. The appointment brings experience from senior executive roles at major medical technology and industrial companies. For investors watching Cooper Companies at a share price of $60.38, this board change comes after a period of weak stock performance. The stock is down 15.7% over the past 30 days, 25.6% year to date, and 25.9% over the past year, with a 37.9%...

SS Innovations International (NasdaqCM:SSII) opened 2026 with Q1 revenue of about US$11.1 million and a basic EPS loss of US$0.02, while trailing 12 month figures show revenue of roughly US$48.5 million and a basic EPS loss of US$0.05. Over the past reported quarters, revenue has ranged from about US$5.1 million in Q1 2025 to US$14.5 million in Q4 2025, with basic EPS losses moving between roughly US$0.00 and US$0.03 per share. Investors are therefore likely to focus on how efficiently that...

YETI Holdings (YETI) opened 2026 with Q1 revenue of US$380.4 million and basic EPS of US$0.13, alongside trailing twelve month revenue of US$1.9 billion and EPS of US$2.01 that frame the latest quarter against a fuller earnings picture. Over recent quarters the company has seen revenue move from US$351.1 million and EPS of US$0.20 in Q1 2025 through US$583.7 million and EPS of US$0.76 in Q4 2025, setting a clear baseline for how this new print fits into the broader trend. With trailing net...

Escalating conflict in the Middle East, including closures around the Strait of Hormuz and issues at Iran’s Kharg Island terminal, has pushed oil prices higher and put Exxon Mobil (XOM) firmly back in focus for investors. See our latest analysis for Exxon Mobil. At a share price of US$152.78, Exxon Mobil has logged a 24.57% year to date share price return. Its 1 year total shareholder return of 45.19% and 5 year total shareholder return of 212.06% point to strong longer term compounding...

Biohaven Ltd. reported first-quarter 2026 results in the past, narrowing its net loss to US$130.53 million from US$221.68 million a year earlier, while loss per share from continuing operations declined to US$0.88 from US$2.17. On the same day, Biohaven filed an omnibus shelf registration covering a wide range of securities, potentially giving the company considerable flexibility in how it may access capital in the future. With these earnings and the broad shelf registration in mind, we’ll...

In May 2026, Valpak Intelligence announced that its New Mover and New Business audience segments became directly available in LiveRamp’s Data Marketplace, giving marketers, brands, and agencies streamlined access to its postal-anchored identity data across major DSPs, SSPs, CTV platforms, and CRM destinations without separate licensing agreements. This partnership brings Valpak’s decades-built household identity spine, spanning approximately 135 million households and hundreds of millions of...

vTv Therapeutics (VTVT) opened Q1 2026 with reported revenue of US$36.8 million and basic EPS of US$1.94, putting a spotlight on the shift in its income statement after a series of quarterly losses. Over the past year, the company has seen quarterly revenue move from effectively US$0 in early 2025 to US$36.8 million in Q1 2026, while basic EPS has swung from a loss of US$0.77 in Q1 2025 to a profit of US$1.94, indicating a sharp change in how much of each sales dollar is landing on the bottom...

Keros Therapeutics (KROS) has just posted Q1 2026 results, with revenue of US$0.4 million, a basic EPS loss of US$1.21 and a net loss of US$23.7 million, setting the tone for the quarter at a share price of US$10.99. The company has seen quarterly revenue move from US$211.2 million in Q1 2025 to US$0.4 million in Q1 2026, while basic EPS shifted from a profit of US$3.66 to a loss of US$1.21. This puts the spotlight on how changes in revenue expectations and potential margin developments could...

In early May 2026, Vertex Pharmaceuticals filed a new US$2.87 billion shelf registration for 6,400,000 common shares tied to its employee stock ownership plan after closing several earlier ESOP-related shelf programs, alongside reporting first-quarter 2026 revenue of US$2,986.9 million and net income of US$1,031.4 million. At the same time, Vertex expanded access for its one-time CRISPR/Cas9 therapy CASGEVY through a reimbursement agreement with Germany’s GKV-Spitzenverband and reaffirmed...

Robotaxi expansion puts DiDi Global (DIDI.Y) in focus DiDi Global (DIDI.Y) is drawing attention after moving faster on autonomous driving, securing a road test license in Beijing for its latest robotaxi and preparing pilot programs in the UAE. See our latest analysis for DiDi Global. Despite the robotaxi progress, recent momentum has been weak. The share price is US$3.58 with a year to date share price return down 35.61%, while the 3 year total shareholder return is 12.23%, hinting at a mixed...